Loading...
XTAE
TKUN
Market cap8mUSD
Apr 03, Last price  
36.90ILS
1D
4.83%
1Q
-0.81%
Jan 2017
-99.17%
Name

Tikun Olam Cannbit Pharmaceuticals Ltd

Chart & Performance

D1W1MN
No data to show
P/E
P/S
70.89
EPS
Div Yield, %
Shrs. gr., 5y
52.80%
Rev. gr., 5y
%
Revenues
44m
-10.28%
002,596,00000000021,659,00037,030,00049,297,00044,228,000
Net income
-89m
L+84.28%
21,781,000-20,175,000-13,374,000-4,106,000-2,829,000-902,000-441,000-21,173,000-10,888,000-32,941,000-32,651,000-48,235,000-88,886,000
CFO
-3m
L-83.40%
-3,040,000-2,937,000-2,423,000-1,969,000-2,434,000-532,000-439,000-1,758,000-3,356,000-24,378,000-23,173,000-18,216,000-3,024,000
Dividend
Dec 28, 201128.2269 ILS/sh

Profile

Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. It also provides training and patient care services. The company is based in Nof Hagalil, Israel.
IPO date
Mar 01, 2000
Employees
102
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
44,228
-10.28%
49,297
33.13%
Cost of revenue
58,365
62,228
Unusual Expense (Income)
NOPBT
(14,137)
(12,931)
NOPBT Margin
Operating Taxes
25
12
Tax Rate
NOPAT
(14,162)
(12,943)
Net income
(88,886)
84.28%
(48,235)
47.73%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,520
21,068
BB yield
Debt
Debt current
13,605
11,752
Long-term debt
12,528
15,277
Deferred revenue
Other long-term liabilities
8,743
5,188
Net debt
14,759
18,341
Cash flow
Cash from operating activities
(3,024)
(18,216)
CAPEX
(1,095)
(11,908)
Cash from investing activities
(727)
(11,126)
Cash from financing activities
8,639
17,682
FCF
60,409
(21,097)
Balance
Cash
6,644
1,756
Long term investments
4,730
6,932
Excess cash
9,163
6,223
Stockholders' equity
(242,700)
(148,684)
Invested Capital
304,548
290,051
ROIC
ROCE
EV
Common stock shares outstanding
63,017
50,794
Price
Market cap
EV
EBITDA
44,573
39,270
EV/EBITDA
Interest
2,301
1,767
Interest/NOPBT